Patients with metastatic colorectal cancer harboring RAS mutations do not benefit from monoclonal antibodies blocking the EGFR 3 and may even have a detrimental effect from treatment with EGFR‐inhibitors 4. This evidence concerns the gene EGFR and metastatic colorectal cancer.